Pharmaceutical company Oncopeptides AB (Nasdaq Stockholm:ONCO) said on Wednesday that it is relaunching patient enrolment to its clinical programme for melflufen (melphalan flufenamide) following a temporary recruitment pause due to the COVID-19 pandemic.
Patient enrolment will start as soon as possible in the ANCHOR combination study, the BRIDGE study and the AL Amyloidosis study, while the LIGHTHOUSE combination study will start after the summer.
The temporary pause did not impact the pivotal phase 2 HORIZON study and the company is on track to submit a file to the US FDA by the end of Q2.
Melflufen is a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumour cells. It displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.
The clinical programme will be resume at sites where local regulations and patient safety enable a restart and where recruitment, treatment and adherence to protocol, as well as safety and data monitoring, are feasible, the company stated.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial